Preconditioning Frailty Phenotype Influences Survival and Relapse for Older Allogeneic Transplantation Recipients.

Autor: Sung AD; Department of Hematologic Malignancies and Cellular Therapy, Duke University Medical Center, Durham, North Carolina., Koll T; Division of Geriatrics, Gerontology, and Palliative Medicine, University of Nebraska Medical Center, Omaha, NE., Gier SH; Division of Hematology and Oncology, Perelman School of Medicine, Philadelphia, Pennsylvania., Racioppi A; Department of Hematologic Malignancies and Cellular Therapy, Duke University Medical Center, Durham, North Carolina., White G; Division of Hematology and Oncology, Perelman School of Medicine, Philadelphia, Pennsylvania., Lew M; Department of Hematologic Malignancies and Cellular Therapy, Duke University Medical Center, Durham, North Carolina., Free M; Division of Geriatrics, Gerontology, and Palliative Medicine, University of Nebraska Medical Center, Omaha, NE., Agarwal P; Division of Oncology and Hematology, University of Nebraska Medical Center, Omaha, Nebraska., Bohannon LM; Department of Hematologic Malignancies and Cellular Therapy, Duke University Medical Center, Durham, North Carolina., Johnson EJ; Department of Hematologic Malignancies and Cellular Therapy, Duke University Medical Center, Durham, North Carolina., Selvan B; Department of Hematologic Malignancies and Cellular Therapy, Duke University Medical Center, Durham, North Carolina., Babushok DV; Division of Hematology and Oncology, Perelman School of Medicine, Philadelphia, Pennsylvania., Frey NV; Division of Hematology and Oncology, Perelman School of Medicine, Philadelphia, Pennsylvania., Gill SI; Division of Hematology and Oncology, Perelman School of Medicine, Philadelphia, Pennsylvania., Hexner EO; Division of Hematology and Oncology, Perelman School of Medicine, Philadelphia, Pennsylvania., Martin M; Division of Hematology and Oncology, Perelman School of Medicine, Philadelphia, Pennsylvania., Perl AE; Division of Hematology and Oncology, Perelman School of Medicine, Philadelphia, Pennsylvania., Pratz KW; Division of Hematology and Oncology, Perelman School of Medicine, Philadelphia, Pennsylvania., Luger SM; Division of Hematology and Oncology, Perelman School of Medicine, Philadelphia, Pennsylvania., Chao NJ; Department of Hematologic Malignancies and Cellular Therapy, Duke University Medical Center, Durham, North Carolina., Fisher AL; Division of Geriatrics, Gerontology, and Palliative Medicine, University of Nebraska Medical Center, Omaha, NE., Stadtmauer EA; Division of Hematology and Oncology, Perelman School of Medicine, Philadelphia, Pennsylvania., Porter DL; Division of Hematology and Oncology, Perelman School of Medicine, Philadelphia, Pennsylvania., Loren AW; Division of Hematology and Oncology, Perelman School of Medicine, Philadelphia, Pennsylvania., Bhatt VR; Division of Oncology and Hematology, University of Nebraska Medical Center, Omaha, Nebraska., Gimotty PA; Department of Biostatistics, Epidemiology and Informatics Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania., McCurdy SR; Division of Hematology and Oncology, Perelman School of Medicine, Philadelphia, Pennsylvania. Electronic address: shannon.mccurdy@pennmedicine.upenn.edu.

Publikováno v: Transplantation and cellular therapy [Transplant Cell Ther] 2024 Apr; Vol. 30 (4), pp. 415.e1-415.e16. Date of Electronic Publication: 2024 Jan 17.